Dr. Mehmet Sitki Copur, MD

Dr. Copur practices at Mary Lanning Healthcare in Hastings, Nebraska, part of Mary Lanning Healthcare.

Dr. Copur's NPI, 1871517433, was assigned on July 27, 2006. Dr. Copur holds Nebraska license 19712.

Dr. Copur's primary practice is Mary Lanning Healthcare, at 715 N St Joseph Ave, Hastings, NE 68901 in Adams County. The practice phone is (402) 463-4521.

Dr. Copur's primary practice is Mary Lanning Healthcare in Hastings, Nebraska, part of Mary Lanning Healthcare. Dr. Copur is also affiliated with Nebraska Medical Center. The medical group on file is Mary Lanning Healthcare. Dmand AI also links Dr. Copur to 3 more hospitals and 1 skilled nursing facility, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Copur practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Copur's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Copur's licenses on file in 3 states: Nebraska, Connecticut and Maryland.

CMS data shows 1,685 Medicare services from Dr. Copur across 5 procedure codes in 2024, for 420 Medicare patients. Medicare paid $77,958 for them.

CMS counts 420 Medicare patients who saw Dr. Copur in 2024. The largest group is 65 to 74, with 197 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Copur's median patient age at 73, with 60% women.

In 2024, Dr. Copur wrote 1,467 Medicare Part D claims for 248 patients. 78% of them were for generic drugs. CMS names the drug for 1,182 of them, across 38 drugs with 11 or more claims each, at $2,430,826 in total drug cost. In 2023, CMS named 1,164 claims across 40 drugs.

Dr. Copur accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 65 papers to Dr. Copur, published from 2010 to 2024. 2019 was the busiest year, with 11. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms and Lung Neoplasms. Dr. Copur has published most often in Oncology (Williston Park). Dr. Copur's most frequent co-authors are Ryan C. Ramaekers, MD, Dron Gauchan, MD and Douglas A. Clark, MD.

Dmand AI links Dr. Copur to 11 clinical trials, 8 of them phase 3 studies. 11 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Breast Carcinoma In Situ. National Cancer Institute (NCI) sponsors the most, 8. Open Payments lists research payments to Dr. Copur that name 1 trial.

CMS Open Payments shows 899 general payments to Dr. Copur from 69 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Bristol-Myers Squibb Company paid the most, $29,743. It also lists 3 research payments totaling $1,950 from 2016 to 2020, naming 1 clinical trial.